Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
| ▸ | GABRE | P78334 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6371199 | 1.00 | EPHX1 (0.47) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL384924 | 1.00 | EPHX1 (0.47) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL31109672 | 0.89 | KCNH2 (0.41) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL825689 | 0.89 | KCNH2 (0.41) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL825809 | 0.89 | KCNH2 (0.41) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL154765 | 0.85 | — | — | |
| SCHEMBL19138062 | 0.85 | — | — | |
| SCHEMBL154766 | 0.85 | — | — | |
| SCHEMBL1802725 | 0.82 | EPHX1 (0.45) | EPHX1POLBGABRPGABRDGABRA1 | |
| SCHEMBL1802729 | 0.82 | EPHX1 (0.45) | EPHX1POLBGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017572-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2022-01-20 | — | — | US | claimed |
| US-20190255141-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2019-08-22 | — | — | US | claimed |
| EP-3472179-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | Erasmus University Medical Center Rotterdam (NL) | 2019-04-24 | — | — | EP | claimed |
| WO-2017217855-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2017-12-21 | — | — | WO | claimed |
| US-9796766-B2 | Potent and selective inhibitors of NAV1.3 and NAV1.7 | AMGEN INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2016-10-20 | — | — | US | claimed |
| US-9340590-B2 | Potent and selective inhibitors of NaV1.3 and NaV1.7 | AMGEN INC. (US) | 2016-05-17 | — | — | US | claimed |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2014-03-13 | — | — | US | claimed |
| EP-2686340-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | Amgen Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012125973-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2012-09-20 | — | — | WO | claimed |
| EP-1991572-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | BIOGEN HEMOPHILIA INC. | 2007-11-01 | — | — | US | claimed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| WO-2026043376-A1 | TRANS-CYCLOOCTENE FORMULATIONS | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2026-02-26 | — | — | WO | disclosed |
| EP-4676542-A1 | TRANS-CYCLOOCTENE WITH IMPROVED T-LINKER | Tagworks Pharmaceuticals B.V. (NL) | 2026-01-14 | — | — | EP | disclosed |
| US-20250313835-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | BIORCHESTRA CO., LTD. (KR) | 2025-10-09 | — | — | US | disclosed |
| EP-0802916-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC (CA) | 1997-10-29 | — | — | EP | disclosed |
| WO-1996040743-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996037497-A1 | LOW MOLECULAR WEIGHT BICYCLIC-UREA TYPE THROMBIN INHIBITORS | BIOCHEM PHARMA INC. (CA) | 1996-11-28 | — | — | WO | disclosed |
| WO-1996019483-A1 | LOW MOLECULAR WEIGHT BICYCLIC THROMBIN INHIBITORS | BIOCHEM PHARMA INC. (CA) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | EPHX1 4052/4885POLB 2041/4885GABRP 505/4885 |
| US-20190255141-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | NGLY1, GRM3, NR0B2 | EPHX1 3405/4885POLB 2810/4885GABRP 1258/4885 |
| US-20220017572-A1 | GEMINOID LIPOPEPTIDE COMPOUNDS AND THEIR USES | NGLY1, NR2C2, NR2E1 | EPHX1 3192/4885POLB 2689/4885GABRP 1082/4885 |
| US-20070254831-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn | FCGRT, FCGR3B, FCGR1A | EPHX1 3281/4885POLB 4277/4885GABRP 465/4885 |
| US-20250313835-A1 | MICELLAR NANOPARTICLES AND USES THEREOF | HNRNPLL, UACA, POLRMT | EPHX1 3687/4885POLB 661/4885GABRP 1998/4885 |
| US-20160304570-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | EPHX1 4052/4885POLB 2041/4885GABRP 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.